Aggrastat

Known as: Merck Frosst brand of tirofiban hydrochloride monohydrate, Agrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
This study aims to investigate the short-term efficacy and safety of intracoronary tirofiban administration during emergency… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2015
2015
We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with ST-segment… (More)
Is this relevant?
2013
2013
BACKGROUND We investigated whether an additional intracoronary tirofiban bolus administration following upstream intravenous… (More)
Is this relevant?
2011
2011
Objective To observe the efficacy and the safety with intracoronary use of tirofiban therapy in acute myocardium infarction… (More)
Is this relevant?
2010
2010
Editor—We read with interest the report of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of… (More)
Is this relevant?
2007
2007
Objective To study the effect and safety of tirofiban hydrochlorid in patients with acute coronary syndromes (ACS) during their… (More)
Is this relevant?
2005
2005
Glycoprotein IIb/IIIa inhibitor therapy during primary percutaneous coronary intervention (PCI) decreases the incidence of major… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
Acute peripheral arterial occlusive disease is an important factor affecting the mobility and mortality rate of elderly patients… (More)
Is this relevant?
2003
2003
The authors investigated the effects of the platelet glycoprotein IIb/IIIa platelet inhibitor, tirofiban, on stent thrombosis in… (More)
Is this relevant?
Review
2001
Review
2001
Therapy involving the use of anti-GPIIb-IIIa inhibitors has progressively evolved in recent years for patients undergoing… (More)
Is this relevant?